Enovis Corp Files Definitive Proxy Statement (DEF 14A)

Ticker: ENOV · Form: DEF 14A · Filed: Apr 5, 2024 · CIK: 1420800

Enovis Corp DEF 14A Filing Summary
FieldDetail
CompanyEnovis Corp (ENOV)
Form TypeDEF 14A
Filed DateApr 5, 2024
Risk Level
Pages15
Reading Time18 min
Sentimentneutral

Sentiment: neutral

Topics: DEF 14A, Enovis Corp, Executive Compensation, Proxy Statement, Corporate Governance

TL;DR

<b>Enovis Corp has filed its Definitive Proxy Statement (DEF 14A) detailing executive compensation and corporate governance information.</b>

AI Summary

Enovis CORP (ENOV) filed a Proxy Statement (DEF 14A) with the SEC on April 5, 2024. Enovis Corp filed a DEF 14A on April 5, 2024, for the period ending May 20, 2024. The filing includes data for fiscal years 2020, 2021, 2022, and 2023. The company was formerly known as Colfax Corp, with a name change date of December 10, 2007. Enovis Corp is incorporated in Delaware and its fiscal year ends on December 31. The company's business and mailing address is located in Wilmington, DE.

Why It Matters

For investors and stakeholders tracking Enovis CORP, this filing contains several important signals. This filing provides crucial details on executive compensation, including stock awards and option awards for PEO and Non-PEO members across multiple fiscal years. As a DEF 14A, this document is essential for shareholders to understand how executive pay is structured and to make informed voting decisions at the upcoming annual meeting.

Risk Assessment

Risk Level: — Enovis CORP shows moderate risk based on this filing. The filing is a routine DEF 14A, which is standard for public companies and does not indicate any unusual financial or operational events.

Analyst Insight

Shareholders should review the executive compensation details and voting proposals within this DEF 14A to make informed decisions at the upcoming annual meeting.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Enovis Corp)
  • 2020-01-01 — Reporting Period Start (Data for fiscal years)
  • 2023-12-31 — Reporting Period End (Data for fiscal years)

Key Players & Entities

  • Enovis Corp (company) — Filer
  • Colfax Corp (company) — Former company name
  • 2024-04-05 (date) — Filing date
  • 2024-05-20 (date) — Period of report
  • DE (location) — State of incorporation and business address
  • 2007-12-10 (date) — Date of name change

FAQ

When did Enovis CORP file this DEF 14A?

Enovis CORP filed this Proxy Statement (DEF 14A) with the SEC on April 5, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Enovis CORP (ENOV).

Where can I read the original DEF 14A filing from Enovis CORP?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Enovis CORP.

What are the key takeaways from Enovis CORP's DEF 14A?

Enovis CORP filed this DEF 14A on April 5, 2024. Key takeaways: Enovis Corp filed a DEF 14A on April 5, 2024, for the period ending May 20, 2024.. The filing includes data for fiscal years 2020, 2021, 2022, and 2023.. The company was formerly known as Colfax Corp, with a name change date of December 10, 2007..

Is Enovis CORP a risky investment based on this filing?

Based on this DEF 14A, Enovis CORP presents a moderate-risk profile. The filing is a routine DEF 14A, which is standard for public companies and does not indicate any unusual financial or operational events.

What should investors do after reading Enovis CORP's DEF 14A?

Shareholders should review the executive compensation details and voting proposals within this DEF 14A to make informed decisions at the upcoming annual meeting. The overall sentiment from this filing is neutral.

How does Enovis CORP compare to its industry peers?

Enovis Corp operates in the orthopedic, prosthetic, and surgical appliances & supplies industry.

Are there regulatory concerns for Enovis CORP?

As a public company, Enovis Corp is subject to SEC regulations and filing requirements, including the DEF 14A for proxy solicitations.

Industry Context

Enovis Corp operates in the orthopedic, prosthetic, and surgical appliances & supplies industry.

Regulatory Implications

As a public company, Enovis Corp is subject to SEC regulations and filing requirements, including the DEF 14A for proxy solicitations.

What Investors Should Do

  1. Review the executive compensation tables for PEO and Non-PEO members for fiscal years 2020-2023.
  2. Examine any proposals presented for shareholder vote, such as director elections or advisory resolutions.
  3. Note the company's former name (Colfax Corp) and the date of the name change.

Key Dates

  • 2024-04-05: Filing Date — Definitive Proxy Statement (DEF 14A) filed.
  • 2024-05-20: Period of Report — The reporting period for the DEF 14A.
  • 2007-12-10: Former Company Name Change — Date Enovis Corp changed its name from Colfax Corp.

Year-Over-Year Comparison

This filing is a DEF 14A, which is a standard disclosure document. No specific comparative data from a prior filing was provided in the text.

Filing Stats: 4,385 words · 18 min read · ~15 pages · Grade level 17 · Accepted 2024-04-05 16:06:25

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 41 Summary Compensation Table 41 Grants of Plan-Based Awards for 2023 43 Outstanding Equity Awards at 2023 Fiscal Year-End 44 Option Exercises and Stock Vested During Fiscal 2023 47 Nonqualified Deferred Compensation 48 Potential Payments Upon Termination or Change of Control 52 CEO PAY RATIO DISCLOSURE 53 PAY-VERSUS-PERFORMANCE 54 Table of Contents EQUITY COMPENSATION PLAN INFORMATION 57 PROPOSAL 3 APPROVAL OF NAMED EXECUTIVE OFFICERS' COMPENSATION, ON A NON-BINDING ADVISORY BASIS ("SAY-ON-PAY") 58 Why You Should Approve Our Executive Compensation Program 58 Vote Required 58 Board Recommendation 58 PROPOSAL 4 APPROVAL OF AN AMENDMENT TO THE ENOVIS CORPORATION 2020 OMNIBUS INCENTIVE PLAN 59 Share Request Background 59 Highlights of the Amended 2020 Plan 59 Summary of Material Terms of the 2020 Plan 60 Share Usage 63 Federal Income Tax Consequences 65 Existing Plan Benefits to Named Executive Officers and Others 66 Registration with the SEC 68 Equity Compensation Plan Information 68 Why You Should Approve the Amendment to the Enovis Corporation 2020 Omnibus Incentive Plan 68 Vote Required 68 Board Recommendation 68 PROPOSAL 5 APPROVAL OF AN AMENDMENT TO THE COMPANY'S CERTIFICATE OF INCORPORATION TO REFLECT NEW DELAWARE LAW PROVISIONS REGARDING OFFICER EXCULPATION 69 Background 69 Impact of the Proposed Amendment 70 Why You Should Approve the Proposed Amendment 70 Vote Required 70 Board Recommendation 70 BENEFICIAL OWNERSHIP OF OUR COMMON STOCK 71 GENERAL MATTERS 73 Outstanding Stock and Voting Rights 73 Stockholder Proposals and Nominations 74 Delivery of Documents to Stockholders Sharing an Address 74 Additional Information 75 Other Matters 75 Appendix A A-1 Special Note Regarding Forward-Looking Statements This proxy statement (this "Proxy Statement") includes forward-looking state

Executive Compensation (page 27)

Executive Compensation (page 27) We strive to create a compensation program for our team members, including our executives, that provides a compelling and engaging opportunity to attract, retain and motivate the best talent. We believe this results in performance-driven leadership that is aligned to achieve our financial and strategic objectives with the intention to deliver superior long-term returns to our stockholders. Our compensation program includes the following key features: We link rewards to performance and foster a team-based approach by setting clear objectives that, if achieved, will contribute to our overall success; We emphasize long-term stockholder value creation by using performance-based restricted stock units, stock options and time-based restricted stock units, in combination with a stock ownership policy, to deliver long-term compensation incentives while minimizing risk-taking behaviors that could negatively affect long-term results; We set Annual Incentive Plan operational and financial performance targets based on the results of our Board's strategic planning process and corporate budget, and provide payouts that vary significantly from year-to-year based on the achievement of those targets; and We believe the design of our overall compensation program, as well as our internal controls and policies, serve to limit excessive risk-taking behavior, as described further on page 38. Say-on-Pay: Advisory Vote to Approve the Compensation of our Named Executive Officers (page 58) We are asking our stockholders to approve on an advisory basis the compensation of our named executive officers. We believe our compensation programs and practices are appropriate and effective in implementing our compensation philosophy, and our focus remains on linking compensation to performance while aligning the interests of management with those of our stockholders. Our Board of Directors has unanimously recommended that stockholders vote FOR the approva

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.